How Much Does Belsomra (Suvorexant) Cost in South Dakota in 2026?

South Dakota Retail Pricing for Suvorexant in 2026

The average cash-pay cost for suvorexant at South Dakota retail pharmacies sits near $85 per month in 2026, a steep drop from Merck's $340 list price for branded Belsomra. Generic suvorexant availability has pushed prices down considerably since the branded product first reached the market.

Pricing varies by pharmacy and location. Larger chain pharmacies in Sioux Falls, Rapid City, and Aberdeen often offer lower prices through volume purchasing, while independent rural pharmacies may charge more. The FDA-approved labeling for Belsomra lists four dose strengths (5 mg, 10 mg, 15 mg, and 20 mg), and cost differences between strengths at the retail level tend to be minimal for generic formulations [1]. GoodRx-style discount cards, which are not insurance, can sometimes push the price below $70 at select SD locations. Patients should compare pricing at multiple pharmacies, as retail cash prices can differ by 30% or more within the same city.

Suvorexant belongs to the dual orexin receptor antagonist (DORA) class, a mechanism distinct from older sedative-hypnotics like benzodiazepines and Z-drugs. The original phase 3 trial by Herring et al. (2014) demonstrated that suvorexant improved subjective total sleep time by approximately 20 minutes over placebo at four weeks, with sustained benefit through three months in adults with insomnia disorder [2]. This clinical profile, combined with a lower abuse liability than Schedule IV benzodiazepines according to FDA scheduling review data, makes suvorexant a commonly prescribed option for chronic insomnia [3].

South Dakota Medicaid Coverage Status

South Dakota Medicaid does not cover Belsomra or generic suvorexant as of 2026. The state's preferred drug list excludes DORAs in favor of less expensive alternatives such as generic zolpidem, trazodone, and doxepin.

Patients enrolled in South Dakota Medicaid who need suvorexant specifically can request a prior authorization exception, though approval rates for non-formulary sleep medications remain low. The American Academy of Sleep Medicine (AASM) clinical practice guideline recommends suvorexant as a treatment option for sleep-onset and sleep-maintenance insomnia, which can support a medical necessity argument when first-line agents have failed or are contraindicated [4]. Documentation of prior therapeutic failures (typically two or more formulary alternatives) strengthens the appeal.

South Dakota expanded Medicaid eligibility under the Affordable Care Act beginning July 2023, increasing the enrolled population. The expanded formulary, however, did not add DORAs. Beneficiaries should also be aware that federal Medicaid drug rebate requirements obligate states to cover most FDA-approved drugs if a rebate agreement exists, but states retain the authority to impose prior authorization and step therapy requirements [5]. A provider willing to file the PA paperwork and document clinical rationale gives the patient the best chance at an exception.

Insurance Coverage Across South Dakota Plans

Most major commercial insurance plans operating in South Dakota, including Avera Health Plans, Sanford Health Plan, and national carriers like UnitedHealthcare and Blue Cross Blue Shield of South Dakota, cover suvorexant with prior authorization or step therapy requirements.

Step therapy protocols typically require documented failure of at least one generic sedative-hypnotic (often zolpidem or eszopiclone) before the plan approves suvorexant. The 2017 ACP clinical guideline on insomnia management supports cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy reserved for patients who do not respond adequately [6]. Insurers frequently cite this guideline when requiring step therapy documentation.

Typical commercial copays for suvorexant under South Dakota plans range from $30 to $75 per month on a preferred specialty or non-preferred brand tier. Employer-sponsored plans with three-tier formularies usually place generic suvorexant on Tier 2, while branded Belsomra lands on Tier 3 or higher [7]. Patients should verify their specific formulary placement by calling the number on the back of their insurance card or checking the plan's online formulary tool.

The FDA's Orange Book confirms that generic suvorexant products have been approved via ANDA, which gives insurers the option to require generic substitution and deny coverage for brand-name Belsomra [8]. South Dakota follows standard generic substitution laws, meaning pharmacists may (and often will) dispense the generic unless the prescriber writes "dispense as written."

The Merck Savings Card and Other Discount Programs

Merck offers a savings card for branded Belsomra that can reduce out-of-pocket costs to $0 for commercially insured patients. The card is not valid for patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligibility requires active commercial insurance with Belsomra on formulary. The savings card covers the difference between the patient's copay and $0 (up to a maximum annual benefit, which Merck sets each calendar year). Patients can enroll through the Belsomra website or receive a card from their prescriber's office. Because generic suvorexant is now available, some patients find the generic cash-pay price competitive with or lower than the branded copay even after the savings card, so a direct cost comparison is worthwhile.

Additional discount avenues in South Dakota include manufacturer patient assistance programs (PAPs) for uninsured patients meeting income thresholds, pharmacy discount cards, and 340B pricing at qualifying federally qualified health centers (FQHCs). South Dakota has several HRSA-funded health centers in Sioux Falls, Pine Ridge, Rapid City, and other communities where 340B drug pricing could reduce suvorexant costs substantially [9]. The HRSA 340B program requires covered entities to pass savings to eligible patients, though implementation varies by site.

Compounded Suvorexant in South Dakota

Compounded suvorexant is legally available in South Dakota through 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidance from FDA's compounding regulations under sections 503A and 503B of the FD&C Act [10].

A 503A pharmacy compounds suvorexant on an individual-patient-prescription basis. Pricing varies widely, but some South Dakota compounding pharmacies offer suvorexant capsules at costs lower than branded retail. Patients should confirm the pharmacy holds a valid South Dakota compounding license and that the compounded product uses USP-grade suvorexant powder.

One consideration: compounded products do not undergo the same bioequivalence testing as FDA-approved generics. The FDA's guidance on compounded drugs notes that compounded medications are not evaluated for safety, effectiveness, or manufacturing quality to the same standard as approved drugs [11]. Patients and prescribers should weigh cost savings against this difference, particularly for a drug where precise dosing affects both efficacy and next-day sedation risk. The Herring et al. trial data showed dose-dependent increases in next-morning somnolence, with the 20 mg dose producing significantly more residual sedation than the 10 mg dose [2].

Telehealth Access for Belsomra in South Dakota

South Dakota permits telehealth prescribing of suvorexant statewide. A prescriber licensed in South Dakota (or holding a valid compact license) can evaluate a patient via synchronous audio-video visit and prescribe Schedule IV controlled substances including suvorexant.

The Ryan Haight Act requires a valid prescriber-patient relationship before controlled substance prescribing via telehealth, but temporary DEA flexibilities expanded during the COVID-19 public health emergency, and subsequent DEA rulemaking has extended telehealth prescribing provisions for Schedule III-V substances [12]. South Dakota's telehealth parity law further supports coverage of telehealth-delivered insomnia evaluations at the same rate as in-person visits under commercial insurance.

Several national telehealth platforms and South Dakota-based practices offer insomnia consultations that can result in a suvorexant prescription. Typical consultation fees range from $75 to $200 for an initial visit. Patients in rural parts of South Dakota, where specialist sleep medicine access is limited, may find telehealth particularly valuable. The AASM's position statement on telehealth supports the use of telemedicine for sleep disorder diagnosis and management [13].

How Suvorexant Compares to Other Insomnia Medications on Cost

Understanding where suvorexant falls on the cost spectrum helps South Dakota patients make informed decisions with their prescribers.

Generic zolpidem, the most prescribed sleep medication in the U.S., costs $5 to $15 per month at South Dakota pharmacies. Generic eszopiclone (Lunesta) runs $15 to $30. Generic suvorexant at $85 per month is significantly more expensive, but the DORA mechanism offers distinct clinical advantages for certain patients. A 2019 network meta-analysis published in The Lancet evaluating 154 randomized trials of pharmacotherapy for insomnia found that suvorexant had a favorable benefit-risk profile for sleep maintenance compared to benzodiazepine receptor agonists, with lower rebound insomnia risk upon discontinuation [14].

Lemborexant (Dayvigo), the other FDA-approved DORA, carries a branded price around $400 per month and does not yet have a generic. For patients whose insurers cover one DORA but not the other, the choice may come down to formulary placement. A head-to-head comparison of suvorexant and lemborexant in the SUNRISE-2 extension study demonstrated comparable efficacy and tolerability profiles, though the trials used different designs and direct comparison data remain limited [15].

Newer entrants include the DORA-2 selective agent daridorexant (Quviviq), priced at approximately $450 per month branded. The IDUN trials for daridorexant showed improved daytime functioning alongside nighttime sleep improvement, a secondary endpoint not consistently met by suvorexant in its original trials [16]. For South Dakota patients focused on cost, generic suvorexant remains the most affordable DORA option.

Tips for Reducing Belsomra Cost in South Dakota

Start with the generic. Asking the prescriber to write for "suvorexant" rather than "Belsomra" allows the pharmacy to fill with any FDA-approved generic, typically at a fraction of the brand cost.

Compare pharmacy prices before filling. South Dakota pharmacies can differ by $20 or more for the same generic. Mail-order pharmacies, including those associated with insurance plans, sometimes offer 90-day supplies at a per-month cost lower than retail. The CMS Medicare Plan Finder can help Medicare beneficiaries compare Part D plan pricing for suvorexant specifically [17].

Ask about therapeutic alternatives. If cost is the primary barrier, a prescriber might consider low-dose doxepin (Silenor), which is available as a low-cost generic and is FDA-approved specifically for sleep-maintenance insomnia at the 3 mg and 6 mg doses [18]. The AASM guideline gives conditional recommendations to both suvorexant and low-dose doxepin for sleep maintenance insomnia, so the substitution is clinically supported when cost drives the decision [4].

Patients prescribed the 20 mg dose who find it effective might discuss with their provider whether 10 mg is sufficient, as the lower dose was also effective in the Herring et al. key trial and would cost the same per tablet but could allow pill-splitting of 20 mg tablets if the formulation permits [2].